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Zinc nutrition is of special practical importance in infants and children. Poor 
zinc absorption causes zinc deficiency, which leads to a broad range of consequences 
such as alopecia, diarrhea, skin lesions, taste disorders, loss of appetite, impaired 
immune function and neuropsychiatric changes and growth retardation, thus potentially 
threatening life in infants and children. In addition to dietary zinc deficiency, inherited 
zinc deficiency, which rarely occurs, is usually found during the infant stage and early 
childhood. Recent molecular genetic studies have identified responsible genes for two 
inherited zinc deficiency disorders, acrodermatitis enteropathica (AE) and transient 
neonatal zinc deficiency (TNZD), clarifying the pathological mechanisms. Both of these 
zinc deficiencies are caused by mutations of zinc transporters, although the mechanisms 
are completely different. AE is an autosomal recessive disorder caused by mutations of 
the ZIP4 gene, consequently resulting in defective absorption of zinc in the small 
intestine. In contrast, TNZD is a disorder caused by mutations of the ZnT2 gene, which 
results in low zinc breast milk in the mother, consequently causing zinc deficiency in 
the breast-fed infant. In both cases, zinc deficiency symptoms are ameliorated by a daily 
oral zinc supplementation for the patients. Zinc is definitely one of the key factors for 
the healthy growth of infants and children, and thus zinc nutrition should receive much 
attention. 
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The optimal growth and development of infants and children requires a 
number of micronutrients. Zinc is one such micronutrient because it plays a pivotal role 
as a structural, catalytic, and signalling component within protein functions. Recent 
human proteomic analyses indicate that about 10% of proteins have been estimated to 
have the potential to bind zinc, which also reflects the indispensability of zinc for 
numerous physiological processes. In fact, zinc is essential for growth and development, 
immune, nervous system and endocrinal functions, and, in particular, is required during 
the first years of the life when the body is growing rapidly. Hence, in developing 
countries, where malnutrition is common, zinc deficiency is still a health problem; zinc 
deficiency increases the risk of morbidity and mortality of young children (1,2). In these 
countries, zinc supplementation in infants and children can prevent and reduce the 
severity of common diseases such as diarrhea, lower respiratory tract infections (3), and 
improve linear growth velocity. In developed countries, zinc deficiency in infants and 
children is much less common. 
Zinc deficiency in infants and children usually occurs through insufficient 
intake of dietary zinc, but it also rarely occurs in an inherited manner, which is 
diagnosed as acrodermatitis enteropathica (AE) or transient neonatal zinc deficiency 
(TNZD) (4). Recent genetic studies have indicated that these conditions can be caused 
by mutations in zinc transporter genes and have clarified the pathological mechanisms 
in patients. This paper reviews current knowledge of zinc deficiency in infants and 
children, emphasizing the molecular basis of hereditary zinc deficiency disorders, AE 
and TNZD, from the standpoint of functions of the responsible zinc transporters. 
 
Requirement of zinc for optimal growth of infants and children 
 Zinc in breast milk is bound to a number of different components including 
casein (14%), albumin (28%), low-molecular weight ligands (29%) and fat (29%) (5). 
Breast milk zinc concentrations, particularly in the first 3 months, are considerably 
higher than those of the maternal serum, which reflects the infant’s requirement of a 
large amount of zinc for growth and development. Compared with full-term infants, 
preterm infants are in negative zinc balance at birth because of the lower capacity for 
gut absorption (6), and thus the demand for zinc increases rapidly in thriving preterm 
infants (7). Hence, the preterm infant has an increased risk of zinc deficiency compared 
with a full-term infant, and symptomatic zinc deficiency has been mostly found in 
breast-fed preterm infants (8,9). Zinc deficiency also rarely occurs in breast-fed, 
full-term infants, in which hereditary AE and TNZD are likely (see below).  
Children also need large amounts of zinc for their rapid growth. 
Recommendations for zinc intake differ between males and females at the age of 15 
years in most countries, but range from 2.9 to 10.0 mg/day in children aged 5 years, 
5.7–15.5 mg/day (boys) and 4.6–15.0 mg/day (girls) in children aged 10–15 years 
(3,10), which can enable severe zinc deficiency to be much less common in developed 
countries. Conversely, zinc deficiency in children is a health problem in developing 
countries, where the dietary needs of zinc may not be met. It is estimated that 4% of the 
global morbidity and mortality of young children between 6 months and 5 years of age 
are attributable to zinc deficiency (1,2).  
 
Two zinc transporters, ZnT and ZIP 
Zinc balance is primarily maintained through a regulated rate of intestinal 
absorption, and gastrointestinal secretion, renal excretion and sloughing of mucosal 
cells and integuments. After absorption, zinc is delivered to the peripheral tissues and 
cells, and then is distributed to the cellular compartments (11). In these processes, zinc 
transporters play crucial roles. In general, zinc transporters are divided into two groups, 
solute carrier 30A (SLC30A) and SLC39A; SLC30A is named Zn transporter (ZnT) and 
SLC39A is named Zrt, Irt-like protein (ZIP) (11,12). ZnT transporters export cytosolic 
zinc into the extracellular space or lumens of intracellular compartments, while ZIP 
transporters import zinc into the cytosol from the extracellular space or lumens of 
intracellular compartments. Most ZnT transporters have six putative transmembrane 
domains (TMDs), while ZIP transporters are thought to have eight TMDs. Both 
transporters are thought to capture zinc transport activity by forming complexes 
(dimers), although there have been no data for the x-ray crystal structure of ZnT and 
ZIP transporters. However, the bacterial ZnT homolog has been x-ray crystalized (13). 
Most ZIP transporters have been shown to be localized in the plasma membrane, while 
most ZnT transporters are localized in the intracellular compartments, and thus are 
functional to mobilize zinc into the lumens. Zinc transporters have crucial functions in 
physiology and dysfunctions of these result in inherited diseases. Thus far, four 
inherited diseases caused by mutations of ZnT and ZIP transporters have been shown, 
and single nucleotide polymorphisms (SNPs) in both transporters related to pathologies 
of the diseases have been identified (4). Thus, the study of these zinc transporters is 
currently of great clinical interest. In zinc deficiency in infants and children, AE (MIM 
No. 201100) and TNZD (MIM No. 608118) have been shown to be caused by 
mutations of ZIP and ZnT transporter genes ZIP4 and ZnT2, respectively (Table 1). In 
both cases, symptoms of zinc deficiency, including erythematous and erosive dermatitis, 
persistent diarrhea, hair loss, and transient growth retardation, are ameliorated by zinc 
supplementation. 
 
Acrodermatitis enteropathica and ZIP4 (SLC39A4) 
AE is an autosomal recessive disorder caused by mutations of the 
ZIP4/SLC39A4 gene (14), consequently resulting in reduced intestinal zinc absorption. 
AE is characterized by eczematous dermatitis, alopecia and diarrhea, typically occurring 
in early infancy but also after weaning in breast-fed infants (14), with an estimated 
frequency of about 1 in 500,000 (15). The zinc deficiency symptoms in patients with 
AE disappear if daily oral zinc supplementation is administered (1–3 mg/kg/day of 
elemental zinc) (15). At present, a myriad of mutations, including missense, nonsense, 
deletion, insertion, or splice-site mutations in the ZIP4/SLC39A4 gene have been 
identified in AE patients (4) since the first reports of the mutations in 2002 (16,17). 
Pathogenic mutations in AE have been shown to result in defects in zinc responsive 
trafficking to the plasma membrane, reduced zinc uptake activity (18), or defects in 
processing, in which the extracellular amino-terminal domain of ZIP4 undergoes 
proteolytic cleavage during extended periods of zinc deficiency (19). The molecular 
mechanism causing severe dermatitis, which is one of the primary features in AE 
patients and severe zinc deficiency, have been shown not to be attributed to allergic 
contact dermatitis, but irritant contact dermatitis, which is caused by loss of Langerhans 
cells with a protective role against ATP-mediated inflammatory signals (20). However, 
those causing alopecia and diarrhea in AE patients remain unknown.  
 
Transient neonatal zinc deficiency and ZnT2 (SLC30A2) 
Zinc deficiency also occurs in breast-fed, full-term infants, which is caused by 
low zinc concentrations in the mother’s breast milk. This type of zinc deficiency is 
called TNZD because zinc deficient symptoms only develop during breast-feeding and 
do not reoccur after weaning. In cases of TNZD, levels of zinc in the milk have been 
reported to be reduced by 75–90% compared with normal levels (21-24), which 
probably defines the onset and course of each patient. The low zinc levels in breast milk 
that result in TNZD are caused by mutations of the ZnT2/SLC30A2 gene in mothers, 
who secret low zinc in their breast milk. Symptoms of TNZD are alleviated with zinc 
supplementation to the infant, but not to the mother. A number of missense mutations 
and a nonsense mutation of the ZnT2/SLC30A2 gene have been identified. Missense 
mutations have been shown to cause aggresomal accumulation, lack of zinc transport 
activity or marked destabilization in ZnT2 protein (21-24). TNZD likely often occurs in 
an autosomal dominant inheritance pattern. 
In mice, “lethal milk” phenotype (MIM No. 602095), a term derived from the 
fact that pups nursed by affected dams die before weaning, is known (25). This 
phenotype is caused by impaired secretion of zinc into the milk and has been shown to 
be the result of homozygous mutations in the SLC30a4/Znt4 gene (25). However, there 
have been no reports of a similar condition in humans. 
 
Remarks 
Zinc is essential for the growth and development of infants and children. Thus, 
developing possible nutritional strategies to overcome zinc deficiency, in addition to 
zinc supplementation, would be beneficial to the health of infants and children globally. 
Moreover, clarification of the molecular mechanisms of AE and TNZD may give 
important clues to preventing premature and full-term normal infants from developing 
zinc deficiency, given that some countries may have an increased risk for TNZD (4). In 
some patients diagnosed with AE, no mutations are found in the ZIP4/SLC39A4 gene 
(26), which may suggest that zinc transporters other than ZIP4 may be involved in the 
zinc absorption process in the small intestine. 
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Table 1. Zinc transporters with mutations and SNPs causing inherited diseases 
 Genes        Diseases                 MIM No.                  Clinical features  
 ZIP4      Acrodermatitis enteropathica         201100     Eczematous dermatitis on the perioral, perianal, and acral areas;                         
                   (AE)                                alopecia; diarrhea; growth retardation and delay; mental       
                                                       slowing; poor wound healing in advanced disease 
                                                       Ameliorated with zinc supplementation (1-3 mg/kg/day) 
 
 ZnT2  Transient neonatal zinc deficiency        608118      Erythematous and erosive dermatitis around the mouth,   
                (TNZD)                                genital region, neck, and fingers; diarrhea; hair loss 




Figure 1. Illustrations of the predicted membrane topology of ZIP4 and ZnT2. 
ZIP4 accumulates in the apical membrane of intestinal epithelial cells to facilitate the 
uptake of zinc from the intestinal lumen during zinc deficiency. The proteolytic 
cleavage (processing, see text) is thought to occur around the CPALLY motif just 
before the first transmembrane domain. ZIP4 is rapidly degraded by lysosomal and 
proteosomal pathways in zinc sufficient conditions (left). ZnT2 is localized in secretory 
vesicles in mammary epithelial cells and plays an indispensable role in the supply of 
zinc into breast milk. This is thought to be mediated through zinc release into the 
alveolar lumen (right). Similar topologies are predicted for other ZIP and ZnT 
transporters. Most ZIP and ZnT transporters have a histidine-rich loop (His-rich loop) in 
the cytosol. 
 
